Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children

BACKGROUND AND OBJECTIVE: Spinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by insufficient levels of survival motor neuron (SMN) protein. Risdiplam (Evrysdi(TM)) increases SMN protein and is approved for the treatment of SMA. Risdiplam has high oral bioavailability and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Cleary, Yumi, Kletzl, Heidemarie, Grimsey, Paul, Heinig, Katja, Ogungbenro, Kayode, Silber Baumann, Hanna Elisabeth, Frey, Nicolas, Aarons, Leon, Galetin, Aleksandra, Gertz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256639/
https://www.ncbi.nlm.nih.gov/pubmed/37148485
http://dx.doi.org/10.1007/s40262-023-01241-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256639/
https://www.ncbi.nlm.nih.gov/pubmed/37148485
http://dx.doi.org/10.1007/s40262-023-01241-7

Ejemplares similares